TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in Oncology
Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings Edinburgh, Scotland – January 19, 2023 – TC Biopharm (Holdings) PLC (NASDAQ: TCBP) (“TC Biopharm” or the “Company”) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, this week announces a strategic collaboration […]
TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid Leukemia
3 Patients Dosed in 5 Patient Safety Cohort Edinburg, Scotland – November 22, 2022 – TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first three patients within its Phase 2b clinical trial of […]
